Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2015, Article ID 356040, 13 pages
http://dx.doi.org/10.1155/2015/356040
Research Article

Regulatory Effect of Iguratimod on the Balance of Th Subsets and Inhibition of Inflammatory Cytokines in Patients with Rheumatoid Arthritis

1Department of Immunology and Microbiology, Shanghai JiaoTong University School of Medicine, Shanghai Institute of Immunology, Shanghai 200025, China
2Guanghua Integrative Medicine Hospital, Shanghai 200052, China

Received 2 August 2015; Accepted 26 October 2015

Academic Editor: Dianne Cooper

Copyright © 2015 Yunzhi Xu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. S. H. Deng, Y. B. Xi, H. Wang et al., “Regulatory effect of vasoactive intestinal peptide on the balance of Treg and Th17 in collagen-induced arthritis,” Cellular Immunology, vol. 265, no. 2, pp. 105–110, 2010. View at Publisher · View at Google Scholar · View at Scopus
  2. F. Benaglio, B. Vitolo, M. Scarabelli et al., “The draining lymph node in rheumatoid arthritis: current concepts and research perspectives,” BioMed Research International, vol. 2015, Article ID 420251, 10 pages, 2015. View at Publisher · View at Google Scholar
  3. C. A. Hitchon and H. S. El-Gabalawy, “The synovium in rheumatoid arthritis,” Open Rheumatology Journal, vol. 5, no. 1, pp. 107–114, 2011. View at Publisher · View at Google Scholar · View at Scopus
  4. A. Manzo, M. Bombardieri, F. Humby, and C. Pitzalis, “Secondary and ectopic lymphoid tissue responses in rheumatoid arthritis: from inflammation to autoimmunity and tissue damage/remodeling,” Immunological Reviews, vol. 233, no. 1, pp. 267–285, 2010. View at Publisher · View at Google Scholar · View at Scopus
  5. G. Schett and E. Gravallese, “Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment,” Nature Reviews Rheumatology, vol. 8, no. 11, pp. 656–664, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Lina, W. Conghua, L. Nan, and Z. Ping, “Combined treatment of etanercept and MTX reverses Th1/Th2, Th17/Treg imbalance in patients with rheumatoid arthritis,” Journal of Clinical Immunology, vol. 31, no. 4, pp. 596–605, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. M.-C. Boissier, G. Chiocchia, N. Bessis et al., “Biphasic effect of interferon-γ in murine collagen-induced arthritis,” European Journal of Immunology, vol. 25, no. 5, pp. 1184–1190, 1995. View at Publisher · View at Google Scholar · View at Scopus
  8. Y. Kageyama, T. Ichikawa, T. Nagafusa, E. Torikai, M. Shimazu, and A. Nagano, “Etanercept reduces the serum levels of interleukin-23 and macrophage inflammatory protein-3 alpha in patients with rheumatoid arthritis,” Rheumatology International, vol. 28, no. 2, pp. 137–143, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. E. M. Moran, R. Mullan, J. McCormick et al., “Human rheumatoid arthritis tissue production of IL-17A drives matrix and cartilage degradation: synergy with tumour necrosis factor-α, Oncostatin M and response to biologic therapies,” Arthritis Research & Therapy, vol. 11, no. 4, article R113, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Cao, R. van Vollenhoven, L. Klareskog, C. Trollmo, and V. Malmström, “CD25brightCD4+ regulatory T cells are enriched in inflamed joints of patients with chronic rheumatic disease,” Arthritis Research & Therapy, vol. 6, no. 4, pp. R335–R346, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. Z. Jiao, W. Wang, R. Jia et al., “Accumulation of FoxP3-expressing CD4+CD25+ T cells with distinct chemokine receptors in synovial fluid of patients with active rheumatoid arthritis,” Scandinavian Journal of Rheumatology, vol. 36, no. 6, pp. 428–433, 2007. View at Publisher · View at Google Scholar · View at Scopus
  12. J. M. Sempere-Ortells, V. Pérez-García, G. Marín-Alberca et al., “Quantification and phenotype of regulatory T cells in rheumatoid arthritis according to disease activity score-28,” Autoimmunity, vol. 42, no. 8, pp. 636–645, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. J. M. R. van Amelsfort, K. M. G. Jacobs, J. W. J. Bijlsma, F. P. J. G. Lafeber, and L. S. Taams, “CD4+CD25+ regulatory T cells in rheumatoid arthritis: differences in the presence, phenotype, and function between peripheral blood and synovial fluid,” Arthritis and Rheumatism, vol. 50, no. 9, pp. 2775–2785, 2004. View at Publisher · View at Google Scholar · View at Scopus
  14. G. M. Han, N. J. O'Neil-Andersen, R. B. Zurier, and D. A. Lawrence, “CD4+CD25high T cell numbers are enriched in the peripheral blood of patients with rheumatoid arthritis,” Cellular Immunology, vol. 253, no. 1-2, pp. 92–101, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. B. Moradi, P. Schnatzer, S. Hagmann et al., “CD4+CD25+/highCD127low/- regulatory T cells are enriched in rheumatoid arthritis and osteoarthritis joints—analysis of frequency and phenotype in synovial membrane, synovial fluid and peripheral blood,” Arthritis Research & Therapy, vol. 16, no. 2, article R97, 2014. View at Publisher · View at Google Scholar
  16. D. Cao, V. Malmström, C. Baecher-Allan, D. Hafler, L. Klareskog, and C. Trollmo, “Isolation and functional characterization of regulatory CD25brightCD4+ T cells from the target organ of patients with rheumatoid arthritis,” European Journal of Immunology, vol. 33, no. 1, pp. 215–223, 2003. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Chen, Z. Guo, W. Ju, B. Ryffel, X. He, and S. G. Zheng, “The development and function of follicular helper T cells in immune responses,” Cellular and Molecular Immunology, vol. 9, no. 5, pp. 375–379, 2012. View at Publisher · View at Google Scholar · View at Scopus
  18. A. Kawakami, M. Tsuboi, S. Urayama et al., “Inhibitory effect of a new anti-rheumatic drug T-614 on costimulatory molecule expression, cytokine production, and antigen presentation by synovial cells,” Journal of Laboratory and Clinical Medicine, vol. 133, no. 6, pp. 566–574, 1999. View at Publisher · View at Google Scholar · View at Scopus
  19. M. Kohno, Y. Aikawa, Y. Tsubouchi et al., “Inhibitory effect of T-614 on tumor necrosis factor-α induced cytokine production and nuclear factor-κB activation in cultured human synovial cells,” Journal of Rheumatology, vol. 28, no. 12, pp. 2591–2596, 2001. View at Google Scholar · View at Scopus
  20. Y. Aikawa, M. Yamamoto, T. Yamamoto, K. Morimoto, and K. Tanaka, “An anti-rheumatic agent T-614 inhibits NF-κB activation in LPS- and TNF-α-stimulated THP-1 cells without interfering with IκBα degradation,” Inflammation Research, vol. 51, no. 4, pp. 188–194, 2002. View at Publisher · View at Google Scholar · View at Scopus
  21. K. Tanaka, T. Yamamoto, Y. Aikawa et al., “Inhibitory effects of anti-rheumatic agent T-614 on immunoglobulin production by cultured B cells and rheumatoid synovial tissues engrafted into SCID mice,” Rheumatology, vol. 42, no. 11, pp. 1365–1371, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. M. Hara, T. Abe, S. Sugawara et al., “Efficacy and safety of iguratimod compared with placebo and salazosulfapyridine in active rheumatoid arthritis: a controlled, multicenter, double-blind, parallel-group study,” Modern Rheumatology, vol. 17, no. 1, pp. 1–9, 2007. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Tanaka, T. Shimotori, S. Makino et al., “Pharmacological studies of the new antiinflammatory agent 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one. 1st communication: antiinflammatory, analgesic and other related properties,” Arzneimittel-Forschung, vol. 42, no. 7, pp. 935–944, 1992. View at Google Scholar · View at Scopus
  24. K. Tanaka, T. Shimotori, Y. Taniguchi, M. Eguchi, and C. Abe, “Pharmacological studies on T-614, a novel antiinflammatory agent—effect on type II collagen-induced arthritis in DBA/1J mice and spontaneous arthritis in MRL/I mice,” International Journal of Immunotherapy, vol. 9, no. 2, pp. 69–78, 1993. View at Google Scholar · View at Scopus
  25. V. Segura-Jimenez, V. A. Aparicio, I. C. Alvarez-Gallardo et al., “Validation of the modified 2010 American College of Rheumatology diagnostic criteria for fibromyalgia in a Spanish population,” Rheumatology, vol. 53, no. 10, pp. 1803–1811, 2014. View at Publisher · View at Google Scholar
  26. K. R. Shi, K. Hayashida, M. Kaneko et al., “Lymphoid chemokine B cell-attracting chemokine-1 (CXCL13) is expressed in germinal center of ectopic lymphoid follicles within the synovium of chronic arthritis patients,” The Journal of Immunology, vol. 166, no. 1, pp. 650–655, 2001. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Rosengren, N. Wei, K. C. Kalunian, A. Kavanaugh, and D. L. Boyle, “CXCL13: A novel biomarker of B-cell return following rituximab treatment and synovitis in patients with rheumatoid arthritis,” Rheumatology, vol. 50, no. 3, Article ID keq337, pp. 603–610, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. D. Jones, B. J. Hamilton, G. J. Challener et al., “Serum C-X-C motif chemokine 13 is elevated in early and established rheumatoid arthritis and correlates with rheumatoid factor levels,” Arthritis Research & Therapy, vol. 16, no. 2, article R103, 2014. View at Publisher · View at Google Scholar · View at Scopus
  29. S. Yamaori, K. Takami, A. Shiozawa, K. Sakuyama, N. Matsuzawa, and S. Ohmori, “In vitro inhibition of CYP2C9-mediated warfarin 7-hydroxylation by iguratimod: possible mechanism of iguratimod-warfarin interaction,” Biological & Pharmaceutical Bulletin, vol. 38, no. 3, pp. 441–447, 2015. View at Publisher · View at Google Scholar
  30. K. Okamura, Y. Yonemoto, C. Okura, T. Kobayashi, and K. Takagishi, “Efficacy of the clinical use of iguratimod therapy in patients with rheumatoid arthritis,” Modern Rheumatology, vol. 25, no. 2, pp. 235–240, 2015. View at Publisher · View at Google Scholar
  31. J. Li, H. Mao, Y. Liang et al., “Efficacy and safety of iguratimod for the treatment of rheumatoid arthritis,” Clinical and Developmental Immunology, vol. 2013, Article ID 310628, 16 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Chabaud, J. M. Durand, N. Buchs et al., “Human interleukin-17: a T cell-derived proinflammatory cytokine produced by the rheumatoid synovium,” Arthritis & Rheumatism, vol. 42, no. 5, pp. 963–970, 1999. View at Publisher · View at Google Scholar · View at Scopus
  33. E. Lubberts, L. A. B. Joosten, B. Oppers et al., “IL-1-independent role of IL-17 in synovial inflammation and joint destruction during collagen-induced arthritis,” The Journal of Immunology, vol. 167, no. 2, pp. 1004–1013, 2001. View at Publisher · View at Google Scholar · View at Scopus
  34. I. B. McInnes and G. Schett, “Cytokines in the pathogenesis of rheumatoid arthritis,” Nature Reviews Immunology, vol. 7, no. 6, pp. 429–442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. K. Hirota, M. Hashimoto, H. Yoshitomi et al., “T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis,” Journal of Experimental Medicine, vol. 204, no. 1, pp. 41–47, 2007. View at Publisher · View at Google Scholar · View at Scopus
  36. R. Nissinen, M. Leirisalo-Repo, M. Tiittanen et al., “CCR3, CCR5, interleukin 4, and interferon-γ expression on synovial and peripheral T cells and monocytes in patients with rheumatoid arthritis,” Journal of Rheumatology, vol. 30, no. 9, pp. 1928–1934, 2003. View at Google Scholar · View at Scopus
  37. L. Carmona, J. J. Gomez-Reino, and BIOBADASER Group, “Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis. Data from the Spanish registry BIOBADASER,” Arthritis Research & Therapy, vol. 8, no. 3, article R72, 2006. View at Publisher · View at Google Scholar
  38. R. R. Ramiscal and C. G. Vinuesa, “T-cell subsets in the germinal center,” Immunological Reviews, vol. 252, no. 1, pp. 146–155, 2013. View at Publisher · View at Google Scholar · View at Scopus
  39. S. Crotty, “Follicular Helper CD4 T cells (TFH),” Annual Review of Immunology, vol. 29, pp. 621–663, 2011. View at Publisher · View at Google Scholar · View at Scopus
  40. N. C. Walsh, L. R. Waters, J. A. Fowler et al., “LKB1 inhibition of NF-kappaB in B cells prevents T follicular helper cell differentiation and germinal center formation,” EMBO reports, vol. 16, no. 6, pp. 753–768, 2015. View at Publisher · View at Google Scholar
  41. K. Raza, F. Falciani, S. J. Curnow et al., “Early rheumatoid arthritis is characterized by a distinct and transient synovial fluid cytokine profile of T cell and stromal cell origin,” Arthritis Research & Therapy, vol. 7, no. 4, pp. R784–R795, 2005. View at Publisher · View at Google Scholar · View at Scopus
  42. F. Du, L.-J. Lü, Q. Fu et al., “T-614, a novel immunomodulator, attenuates joint inflammation and articular damage in collagen-induced arthritis,” Arthritis Research and Therapy, vol. 10, no. 6, p. R136, 2008. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Aikawa, N. Tanuma, T. Shin, S. Makino, K. Tanaka, and Y. Matsumoto, “A new anti-rheumatic drug, T-614, effectively suppresses the development of autoimmune encephalomyelitis,” Journal of Neuroimmunology, vol. 89, no. 1-2, pp. 35–42, 1998. View at Publisher · View at Google Scholar · View at Scopus
  44. A. Fernadez-Martin, E. Gonzalez-Rey, A. Chorny, D. Ganea, and M. Delgado, “Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis,” European Journal of Immunology, vol. 36, no. 2, pp. 318–326, 2006. View at Publisher · View at Google Scholar · View at Scopus
  45. E. Gonzalez-Rey, A. Fernandez-Martin, A. Chorny, and M. Delgado, “Vasoactive intestinal peptide induces CD4+,CD25+ T regulatory cells with therapeutic effect in collagen-induced arthritis,” Arthritis & Rheumatism, vol. 54, no. 3, pp. 864–876, 2006. View at Publisher · View at Google Scholar · View at Scopus